{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T06:10:23Z","timestamp":1759385423148},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,9,15]]},"DOI":"10.2169\/internalmedicine.1142-22","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T22:11:57Z","timestamp":1673734317000},"page":"2731-2735","source":"Crossref","is-referenced-by-count":5,"title":["Successful Treatment with Definitive Concurrent Chemoradiotherapy Followed by Durvalumab Maintenance Therapy in a Patient with Tracheal Adenoid Cystic Carcinoma"],"prefix":"10.2169","volume":"62","author":[{"given":"Erika","family":"Mikami","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Nakamichi","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhiro","family":"Nagano","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Misawa","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Tozuka","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuki","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rintaro","family":"Noro","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Maebayashi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Kubokura","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Graduate School of Medicine, Nippon Medical School Musashikosugi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Terasaki","sequence":"additional","affiliation":[{"name":"Department of Analytic Human Pathology, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Seike","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Dodd RN, Slevin NJ. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol 42: 759-769, 2006.","DOI":"10.1016\/j.oraloncology.2006.01.001"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Calzada AP, Miller M, Lai CK, et al. Adenoid cystic carcinoma of the airway: a 30-year review at one institution. Am J Otolaryngol 33: 226-231, 2012.","DOI":"10.1016\/j.amjoto.2011.07.003"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gomez DR, Hoppe BS, Wolden SL, et al. Outcomes and prognostic variables in adenoid cystic carcinoma of the head and neck: a recent experience. Int J Radiat Oncol Biol Phys 70: 1365-1372, 2008.","DOI":"10.1016\/j.ijrobp.2007.08.008"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ha H, Keam B, Ock CY, et al. Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma. Korean J Intern Med 36: 175-181, 2021.","DOI":"10.3904\/kjim.2019.104"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. El Marjany M, Arsalane A, Sifat H, et al. Primary adenoid cystic carcinoma of the trachea: a report of two cases and literature review. Pan Afr Med J 19: 32, 2014.","DOI":"10.11604\/pamj.2014.19.32.4878"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wang H. Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma. Thorac Cancer 8: 729-733, 2017.","DOI":"10.1111\/1759-7714.12506"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Maziak DE, Todd TR, Keshavjee SH, et al. Adenoid cystic carcinoma of the airway: thirty-two-year experience. J Thorac Cardiovasc Surg 112: 1522-1531, 1996.","DOI":"10.1016\/S0022-5223(96)70011-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Urdaneta AI, Yu JB, Wilson LD. Population based cancer registry analysis of primary tracheal carcinoma. Am J Clin Oncol 34: 32-37, 2011.","DOI":"10.1097\/COC.0b013e3181cae8ab"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Madariaga MLL, Gaissert HA. Overview of malignant tracheal tumors. Ann Cardiothorac Surg 7: 244-254, 2018.","DOI":"10.21037\/acs.2018.03.04"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Honings J, Gaissert HA, van der Heijden HF, et al. Clinical aspects and treatment of primary tracheal malignancies. Acta Otolaryngol 130: 763-772, 2010.","DOI":"10.3109\/00016480903403005"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sterman DH, Sztejman E, Rodriguez E, et al. Diagnosis and staging of &quot;other bronchial tumors&quot; . Chest Surg Clin N Am 13: 79-94, 2003.","DOI":"10.1016\/S1052-3359(02)00043-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Bhattasali O, Holliday E, Kies MS, et al. Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: a series of 9 cases and a critical review of the literature. Head Neck 38: 1472-1480, 2016.","DOI":"10.1002\/hed.24262"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hill ME, Constenla DO, A&apos;Hern RP, et al. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 33: 275-278, 1997.","DOI":"10.1016\/S0964-1955(97)00026-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Atagi S, Kawahara M, Yokoyama A, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomized, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 13: 671-678, 2012.","DOI":"10.1016\/S1470-2045(12)70139-0"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Senan S, Brade A, Wnng LH, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 34: 953-962, 2016.","DOI":"10.1200\/JCO.2015.64.8824"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Liang J, Bi N, Wu S, et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol 28: 777-783, 2017.","DOI":"10.1093\/annonc\/mdx009"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ichinose Y, Seto T, Sasaki T, et al. S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706). J Thorac Oncol 6: 2069-2075, 2011.","DOI":"10.1097\/JTO.0b013e3182307e5a"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379: 2342-2350, 2018.","DOI":"10.1056\/NEJMoa1809697"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Wang F, Xie X, Song M, et al. Tumor immune microenvironment and mutational analysis of tracheal adenoid cystic carcinoma. Ann Transl Med 8: 750, 2020.","DOI":"10.21037\/atm-20-3433"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Nightingale J, Lum B, Ladwa R, et al. Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy. Biochim Biophys Acta Rev Cancer 1875: 188523, 2021.","DOI":"10.1016\/j.bbcan.2021.188523"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Mahmood U, Bang A, Chen YH, et al. A randomized phase 2 study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma. Int J Radiat Oncol Biol Phys 109: 134-144, 2021.","DOI":"10.1016\/j.ijrobp.2020.08.018"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sasaki T, Seto T, Yamanaka T, et al. A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L. Br J Cancer 119: 675-682, 2018.","DOI":"10.1038\/s41416-018-0243-2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Shimokawa T, Yamada K, Tanaka H, et al. Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer. Cancer Med 10: 626-633, 2021.","DOI":"10.1002\/cam4.3641"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377: 1919-1929, 2017.","DOI":"10.1056\/NEJMoa1709937"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 40: 1301-1311, 2022.","DOI":"10.1200\/JCO.21.01308"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/18\/62_1142-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T03:23:52Z","timestamp":1694834632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/18\/62_1142-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":25,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1142-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"article-number":"1142-22"}}